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Abstract Parathyroid hormone-related protein (PTHrP) has a
diverse range of proposed biological activities participating in
both extracellular and intracellular signaling. In order to iden-
tify candidate protein e¡ectors, yeast two-hybrid screens were
conducted using mature human PTHrP (residues 1^141) and the
COOH-terminus (residues 107^141). Both PTHrP baits inter-
acted with a L-arrestin 1B fragment, an important component of
G-protein-coupled receptor desensitization and MAPK signal-
ing. Co-immunoprecipitation, in vitro binding assays and colo-
calization experiments con¢rmed this interaction in human cells
and this required residues 122^141 of PTHrP. These ¢ndings
suggest that L-arrestin 1 acts as an e¡ector for a novel function
of PTHrP in cytoplasm. 1 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Parathyroid hormone-related protein (PTHrP) is a humoral
factor secreted from tumors that mimics the actions of para-
thyroid hormone (PTH) on bone and kidney and is the major
cause of hypercalcaemia in patients with cancer [1]. PTHrP is
a key regulator of skeletal development via its interaction with
the PTH1 receptor to in£uence chondrocyte proliferation, dif-
ferentiation and apoptosis [2^5]. It also acts as a poly-func-
tional hormone in several systems in a paracrine/autocrine
manner via PTH-independent mechanisms to in£uence embry-
onic development, cell growth and di¡erentiation [6].
In addition to its extracellular actions, it is evident that
intracellular forms of PTHrP exist which can act via intracrine
pathways. PTHrP forms lacking the pre-pro secretory signal
have been demonstrated to in£uence mechanisms of prolifer-
ation, di¡erentiation and apoptosis, e¡ects that are dependent
on its translocation between the cytoplasm and nucleus [7,8].
Nuclear/nucleolar targeting of PTHrP is required for enhanc-
ing survival of chondrocytes in culture under conditions that
promote apoptosis [7] and also in the breast cancer cell line
MCF-7 [9]. However, in other cell lines such as intestinal cell
line, IEC-6, it has the opposing action [10]. In vascular
smooth muscle cells, the nuclear localization of PTHrP in-
creases cell proliferation, an opposing e¡ect to extracellular
PTHrP on vascular smooth muscle cells to inhibit cell prolif-
eration [11]. The translocation of PTHrP into the nucleus is
dependent on the preservation of the nuclear localization se-
quence (NLS) [7] and occurs via its interaction with importin-
L to mediate nuclear transport of PTHrP in an active GTP-
dependent manner [12]. This translocation is cell cycle regu-
lated and PTHrP is retained in the cytoplasm when phosphor-
ylated [13,14], suggesting active cytoplasmic retention via
phosphorylation by unknown proteins. Upon entering the
nucleus, PTHrP can be translocated to the dense ¢brillar com-
ponents of the nucleoli [7] where it has been shown to bind
RNA, possibly to mediate ribosome synthesis [15].
To further elucidate the function of intracellular PTHrP, we
have used the yeast two-hybrid system to identify interacting
molecules. Mature full-length PTHrP that interacts with the
PTH1R and two other forms, PTHrP (38^94) and PTHrP
(107^141), that exhibit PTH1R-independent functions were
used. L-Arrestin 1B protein was identi¢ed and further con-
¢rmed as an interactor with COOH-terminal 19 residues of
human PTHrP (122^141). This is the ¢rst study to report a
protein interaction with the COOH-terminus of PTHrP and
support a novel role for PTHrP in the cytoplasm that is man-
ifested through L-arrestin 1-mediated pathways.
2. Materials and methods
2.1. Antibodies
Anti-hemagglutinin (HA) mouse monoclonal antibody (12CA5)
was from Roche. Polyclonal antiserum (#R90) to human PTHrP
(67^94) peptide was raised in-house in rabbits, and recognizes a pro-
tein doublet of approximately 46 kDa in immunoblots of cell lysates
overexpressing GFP-PTHrP (1^141). Mouse monoclonal anti-FLAG
antibody M2 was from Sigma Chemical Company (St. Louis, MO,
USA) and polyclonal rabbit anti-glutathione-S-transferase (GST)
antibody (sc-459) was from Santa Cruz Biotechnology. Anti-mouse
IgG conjugated to Texas red (Molecular probes T-862) was used for
immuno£uorescence.
2.2. Expression plasmids
For yeast two-hybrid assays, human PTHrP (1^141), mid region
(38^94), COOH-terminal region PTHrP (107^141) and PTHrP (122^
141) were generated by polymerase chain reaction (PCR) using oligo-
nucleotides obrf 15.171 and 15.172, obrf 15.174 and 15.175, obrf
15.173 and 15.172, and obrf 15.179 and obrf 15.172, respectively, as
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indicated in Table 1, then ligated into the EcoRI and BamHI sited of
pGBT9 to generate in-frame fusion proteins to the GAL4 DNA bind-
ing domain (DNA-BD). For yeast two-hybrid screening, a bidirec-
tional cDNA library in pGAD10 was used (Clontech). FLAG-tagged
human L-arrestin 1B (1^361) was generated using L-arr-3 (sense) and
L-arr-4 (antisense) oligonucleotides for cloning into the HindIII and
XhoI sites of pCDNA3. For HA-tagged PTHrP, ðCOOHÞHA-tagged
PTHrP (1^141), ðNH2ÞHA-PTHrP and ðCOOHÞHA-PTHrP (336^141)
were generated using obrf 15.184 and 15.185, obrf 15.182 and
15.183, and obrf 15.186 and 15.185, respectively (Table 1), then li-
gated into the HindIII and XbaI sites of pCDNA3. For bacterial
expression, GST-PTHrP (38^141) (kindly provided by M. Lam) and
GST-RANKL (kindly provided by F.P. Ross) were used. For local-
ization studies, p-enhanced green £uorescent protein (pEGFP)-CP-
PTHrP (1^141) [14] encoded an in-frame COOH fusion to the GFP
tag. GFP-human L-arrestin 1A was kindly provided by P. Sexton.
2.3. Yeast two-hybrid screens
The yeast two-hybrid system [16] used in this study was the GAL4
Matchmaker 1.0 (Clontech). Saccharomyces cerevisiae strain PJ69-4A
(kindly provided by M. Southey) was transformed with bait con-
structs, clones selected and these were subsequently transformed
with the pGAD10 activation domain cDNA library [17]. Transform-
ants were selected for by growth on media lacking leucine and tryp-
tophan. After 4 days, yeast were replica plated onto media selecting
for activation of the reporter genes, i.e. lacking adenine, histidine,
tryptophan and leucine (WAdHL3). Interacting clones were isolated
and retransformed to con¢rm interaction. Interacting clones were also
transformed alone, and with the empty DNA-BD vector, and an un-
related fusion encoded by DNA-BD-pLAM5P control vector, to test
for autoactivation. Interaction was further assayed by the production
of L-galactosidase to catalyze ONPG over time in the Y190 yeast
strain.
2.4. Cell lysis and co-immunoprecipitation
HEK293 cells were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM)+10% fetal bovine serum (FBS), then transfected for 24^48 h
with 2 Wg of plasmid DNA per well of a six-well plate using FuGENE
(Roche) at 90% con£uency. Cells were harvested using 1 ml of PLC
lysis bu¡er (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1%
Triton X-100, 1 mM EDTA, 1UProtease inhibitors) and disrupted
with a syringe. Lysates were mixed with 1 Wg of anti-FLAG antibody
and incubated for 1 h at 4‡C, followed by addition of 50 Wl of protein
G-agarose beads (Amersham) and incubated for 2 h at 4‡C. Immu-
noprecipitates were washed three times with IP wash bu¡er (20 mM
HEPES pH 7.5, 10% glycerol, 0.1% Triton X-100, 150 mM NaCl),
then analyzed by immunoblotting.
2.5. In vitro binding assays
Protein expression was carried out in XL-1 blue cells with 1 mM
IPTG for 3.5 h at 37‡C. GST fusion proteins were puri¢ed by harvest-
ing 100 ml of cells and lysing by sonication in 5 ml PBS. Cleared
lysates were bound to 50 Wl glutathione Sepharose beads for 30 min at
4‡C. Bound proteins were then normalized to 250 Wg/ml using fresh
beads. Mammalian cell lysates (V1 mg) were incubated with 5 Wg of
a⁄nity-puri¢ed GST fusion protein coupled to 40 Wl of glutathione
Sepharose, for 2 h at 4‡C, then washed four times with 10Uvolume of
lysis bu¡er and analyzed by immunoblotting.
2.6. Immuno£uorescence
HEK293 cells were grown in six-well plates containing poly-L-lysine
(Sigma)-coated coverslips, transfected with recombinant plasmids for
24 h, washed twice with PBS, ¢xed with 3.2% PFA and permeabilized
with 0.5% Triton X-100. Transfected cells were stained with anti-HA
antibody of anti-FLAG antibody. Cells were visualized at 1000U
using a Leica microscope and images acquired using a Bio-Rad
MCR 1024 laser confocal imaging system.
3. Results
3.1. Isolation of protein interactors with human PTHrP
To identify proteins that interact with human PTHrP, three
independent screens of a human placental cDNA library fused
to a GAL4 activation domain were conducted using the full-
length mature PTHrP (1^141), a mid region (38^94) and the
COOH-terminal region (107^141), each fused to a DNA-BD.
Using the PTHrP (1^141) bait, 4.4 million clones were
screened and four clones were found to speci¢cally interact
supporting growth on WAdHL media. 1.2 million clones were
screened with the PTHrP (107^141) bait from which four
clones were also isolated on their ability to interact. Clones
were sequenced and found to be identical in both screens
encoding residues 1^361 of L-arrestin 1B, lacking 49 COOH-
terminal residues. The DNA activation domain (DNA-AD)-L-
arrestin 1B fusion was retransformed with controls and each
of the PTHrP baits, and was demonstrated to speci¢cally
interact with PTHrP (1^141) and PTHrP (107^141), but not
PTHrP (38^94) in both auxotrophic and colorimetric reporter
gene assays (Fig. 1A).
Since sequences of PTHrP interacting with L-arrestin 1B 1^
361 were con¢ned to the COOH-terminus, a bait encoding
human PTHrP (122^141) was cotransformed with DNA-
AD-L-arrestin 1B (1^361) into PJ69-4A yeast (Fig. 1B). Nutri-
tional and lacZ reporter gene readouts demonstrated positive
interaction between human PTHrP (122^141) and human
L-arrestin 1B (1^361), further con¢rming interaction in the
yeast two-hybrid system and indicated involvement of the ex-
treme COOH-terminus of PTHrP.
3.2. PTHrP and L-arrestin 1B form a protein complex
To con¢rm interaction of L-arrestin 1B (1^361) with
PTHrP, bacterially expressed GST-PTHrP (38^141) conju-
Table 1
List of oligonucleotides used for PCR cloning
Oligonucleotide Orientation Sequence
obrf 15.171 S 5P-CCGGAATTCGCTGTGTCTGAACAATCAGCTC-3P
obrf 15.172 A 5P-GACAGGATCCTGCAATCTGTC-3P
obrf 15.173 S 5P-CCGGAATTCACTCGCTCTGCCTGGTTAGAC-3P
obrf 15.174 S 5P-CCGGAATTCGCTACCTCGGAGGTGTCCCCTAAC-3P
obrf 15.175 A 5P-GCCGGATCCTTGCGTTTTCAGGGCTTGCCTTTCTTTTTCTTCCCAG-3P
obrf 15.179 S 5P-GCGGAATTCGAAGGGGACCACCTG-3P
obrf 15.182 S 5P-GCGCCCAAGCTTGGGCCATGTACCCATACGACGTCCCAGACTACGCTGCTGTGTCTGAACATCAGCTCCT-3P
obrf 15.183 A 5P-GGCGCCTCTAGAGCCTCATGCCCTCCGTGAAT-3P
obrf 15.184 S 5P-GGCGCCCAAGCTTGGGCCATGGCTGTGTCTGAACATCAGCTC-3P
obrf 15.185 A 5P-CGCGGCTCTAGAGCTCAAGCGTAGTCTGGGACGTCGTATGGGTAATGCCTCCGTGAATCGAGCTCCAGCGACGTTGT-3P
obrf 15.186 S 5P-GGCGCCCAAGCTTGGATGCAGCGGAGACTGGTTCA-3P
L-arr-3 S 5P-CGCGCGGAAGCTTGGACCATGGGCGACAAAGGGACGCG-3P
L-arr-4 A 5P-CGCGCTCGAGTCACTTGTCATCGTCGTCCTTGTAGTCCTCGTTCTCTGGAACTTCCCGATGC-3P
Restriction enzyme sequences are in bold. S, sense primer; A, antisense primer.
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Fig. 1. A: Yeast cotransformed with pGAD10-L-arrestin 1B and a variety of baits. Activation of transcription of nutritional reporter genes was
assayed by growth on media lacking adenine and histidine, as well as the plasmid markers leucine and tryptophan (WAdHL-). Activation of
lacZ gene transcription was assessed by liquid L-galactosidase assaysV S.E.M. B: Interaction of human PTHrP COOH-terminal baits indicated
with L-arrestin 1B (1^361) by growth on media lacking adenine and histidine (WAdHL3).
Fig. 2. Validation of binding of human PTHrP with L-arrestin 1. A: In vitro binding assays in which GST-PTHrP or negative control (GST-
RANKL) was incubated with mammalian cell lysates expressing FLAG-L-arrestin 1B (1^361) or FLAG tag alone. Whole cell lysate (WCL)
shows L-arrestin 1B (1^361) expression. B: Co-immunoprecipitation of GFP-PTHrP (1^141) with FLAG-L-arrestin 1B (1^361) but not with
negative control FLAG-PA28Q. HEK293 lysates were immunoprecipitated with M2 KFLAG, and detected for the presence of GFP-PTHrP us-
ing R90 KPTHrP antibody.
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gated to glutathione Sepharose was incubated with HEK293
lysates overexpressing FLAG-L-arrestin (1^361). FLAG-L-ar-
restin 1B (1^361) appears as a 45 kDa band in whole cell
lysate. After stringent washing, the presence of FLAG-L-ar-
restin 1B (1^361) was detected on immunoblot when incuba-
ted with GSP-PTHrP and not with a control GST function
(Fig. 2A). Importantly, this interaction was con¢rmed in hu-
man cells using co-immunoprecipitation. HEK293 cells were
cotransfected with GFP or GFP-PTHrP (1^141) and FLAG-
L-arrestin 1B (1^361). GFP-PTHrP co-immunoprecipitated
with FLAG-L-arrestin 1B (1^361) as a 46 kDa protein (Fig.
2B). GFP-PTHrP did not co-immunoprecipitate with a neg-
ative control fusion, FLAG-PA28Q protein. Both of these
binding assays con¢rm the yeast two-hybrid interaction and
provide support for a novel function for PTHrP in vivo.
3.3. Subcellular colocalization of L-arrestin 1 and PTHrP
The subcellular localization of GFP-L-arrestin 1 was com-
pared with that of three forms of HA-PTHrP. Mature PTHrP
containing the secretory signal sequence, ðCOOHÞHA-PTHrP
(336^141) was co-overexpressed in the presence of GFP-L-
arrestin 1 and demonstrated nuclear/nucleolar localization
and co-localized with GFP-L-arrestin 1 around endosome-
like structures located in the cytoplasm and around the nu-
clear periphery (Fig. 3A). The mature form of PTHrP (1^141)
lacking the pre-pro region fused to HA tags at either the
NH2- (Fig. 3B) or the COOH-terminus (Fig. 3C) to exclude
tag interference, demonstrated similar localization patterns,
indicating that PTHrP does not have to be processed via
the secretory pathway in order to interact with L-arrestin 1.
Although PTHrP localized both to the nucleus and cytoplasm,
the localization of GFP-L-arrestin 1 was coincident with some
PTHrP localization in the cytoplasm and around the nucleus
(Fig. 3).
4. Discussion
The yeast two-hybrid system has been employed using func-
tional domains of human PTHrP in order to identify novel
protein partners as targets for function. This study is the ¢rst
to report the isolation of a protein interactor with the COOH-
terminus of human PTHrP, a truncated form of L-arrestin 1B.
The PTHrP interaction with L-arrestin 1B (1^361) was con-
¢rmed by isolation of complexes by co-immunoprecipitation
and in vitro assays. Further characterization of the PTHrP
binding determinant revealed the interaction was dependent
on residues within PTHrP (122^141). Subcellular localization
studies demonstrated that PTHrP was observed on endosome-
like vesicles when overexpressed with GFP-L-arrestin 1, a phe-
nomenon analogous to that observed for ERK1 in which stoi-
chiometrically equal expression of L-arrestin is required for
ERK1Ps endosome and nuclear localization. Both the pre-
pro and mature forms of PTHrP colocalized with GFP-L-ar-
restin 1 on endosome-like vesicles, suggesting that the inter-
action occurs between intracellular forms of PTHrP, possibly
initiated from internal ribosome entry sites to bypass the se-
cretory pathway [18].
L-Arrestins are essential for the desensitization of ligand-
stimulated G-protein-coupled receptors (GPCRs) in two
steps: (1) by altering the a⁄nity of the receptor for the
G-protein and (2) by recruiting the clathrin adapter protein
AP-2 and the NSF protein to signal clathrin-mediated endo-
Fig. 3. Colocalization of HA-tagged PTHrP with GFP-L-arrestin 1. GFP-L-arrestin was cotransfected with either (A) COOH-terminally tagged
HA-PTHrP (336^141), (B) NH2-tHA-tagged PTHrP (1^141), and (C) COOH-HA-tagged PTHrP (1^141). The localization was examined by di-
rect £uorescence of GFP (left) and anti-HA mouse monoclonal with Texas red secondary antibody (center). Colocalization was examined by
overlaying the two images (right). Colocalization around endosome-like structures is indicated by arrows.
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cytosis of the activated receptor [19,20]. In addition, recent
studies have demonstrated that receptor-bound L-arrestins
act as sca¡olds for members of the mitogen-activated protein
kinase (MAPK) pathway such as c-src, raf, ASK1, ERK1/2
and JNK3 [21,22]. The association of these components with
the sca¡old prevents translocation of ERK1/2 to the nucleus,
thereby attenuating its proliferative e¡ects and promoting
phosphorylation of its cytosolic substrates [23,24]. Thus the
subcellular localization and speci¢city of ERK1/2 and its as-
sociated mitogenic potential are controlled by the formation
of the L-arrestin sca¡olding complex, most likely in response
to GPCR activation. By analogy, the interaction of intracel-
lular PTHrP with L-arrestin may allow cytoplasmic nuclear
shuttling of PTHrP to be brought under control of the
L-arrestin/MAPK pathway. In a manner similar to ERK1/2,
the binding of PTHrP to the L-arrestin-MAPK sca¡old may
retain it in the cytosol, therefore preventing the proliferative
e¡ects associated with its uptake into the nucleus.
The association of PTHrP with L-arrestin 1 may bring it
into contact with other components of the L-arrestin-depen-
dent MAPK sca¡old such as ras and c-src as a target for
modi¢cations such as phosphorylation, possibly as a means
of retaining PTHrP in the cytoplasm. The in£uence of mem-
bers of the MAPK pathway such as ras and c-src in modulat-
ing PTHrP expression has been previously demonstrated
[25,26]. At the protein level, the presence of putative phos-
phorylation sites in the COOH-terminal regions of PTHrP
may be potential targets of regulation by these L-arrestin in-
teractors. Alternatively, PTHrP may interact with the L-ar-
restin 1 sca¡old as a means of modulating GPCR signaling,
perhaps to potentiate or antagonize the cellular response to
other extracellular ligands. This novel interaction provides
evidence for a cytoplasmic context for PTHrP function and
this is manifested through a L-arrestin 1-mediated pathway.
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